The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 04, 2012
Filed:
Oct. 31, 2011
Zeling Cai, San Diego, CA (US);
Wei-xing Shi, San Diego, CA (US);
Xuejun P. Liu, San Diego, CA (US);
Jiejun Wu, San Diego, CA (US);
Zeling Cai, San Diego, CA (US);
Wei-Xing Shi, San Diego, CA (US);
Xuejun P. Liu, San Diego, CA (US);
Jiejun Wu, San Diego, CA (US);
Janssen Pharmaceutica NV, Beerse, BE;
Abstract
Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.